Life Sciences

FDA issues warning letters to Ranbanxy

Pharma Compliance Alert, September 24, 2008

Two of generic drug manufacturer Ranbaxy’s plants allegedly violated U.S. current Good Manufacturing Practices (cGMP), prompting the FDA to issue two warning letters and an import advisory, according to an agency release.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular